Potentially practice-changing data was presented at 2018 ASH Annual Meeting and Exposition (December 1–4, 2018; CA, USA), read our round-up to discover the key studies. Highlights include the CASSINI and MAIA trial data,
A personalized prediction scheme for certain chronic blood cancers has been developed, based on new disease classifications.
The ground breaking CAR-T therapy – Kymriah® – is set to become the first personalized cancer therapy available on the NHS.
In this In Focus, we will explore the latest developments and emerging concepts in the field of hematologic malignancies.
Yescarta®, a novel personalized CAR T cell therapy has been approved for use in Europe by the EMA but has received a draft negative guidance from NICE.
The largest ever study of its kind has become the first to definitively show an increased risk of blood cancers in relatives of patients.
In this interview discover some of the challenges in developing CAR-T therapies for solid tumors as well as major milestones in their development and where the field is heading.
Researchers have discovered first leukemia protective gene that is specific to the male-only Y chromosome.
A genetics study has unearthed an unexpected new drug target for acute myeloid leukaemia that could open new avenues to develop effective treatments.
Discover the importance of DNA methylation changes in the identification of potential biomarkers relevant for clinical follow-up and personalized medicine of chronic lymphocytic leukemia.
